Clock Tower




The Center for Health and Social Research

Institute for Community Health Promotion

SUNY Buffalo State



Karl Wende
Karl Wende, Ph.D.
Research Scientist
wendeke@buffalostate.edu
phone: (716) 878-6137
fax: (716) 878-5905






Background and Job Description

Dr. Wende is a Research Scientist in the Center for Health and Social Research at Buffalo State College working as part of the Center's team on a number of grant and contract based projects. Previously he was a Project Coordinator in the Department of Health Behavior, School of Public Health and Health Professions, University at Buffalo, an Epidemiologist with the Eastman Kodak Company, Rochester, NY, and a Project Director/Research Scientist, Data Management and Statistical Office, Department of Neurology, University at Buffalo.

Research Interests:

Dr. Wende's research areas and interests involve occupational and environmental health, substance abuse prevention in adolescents, and developing process and system solutions to promote better and lower cost health in communities. Dr. Wende's current projects include developing data driven methods for delivering school and community based substance abuse prevention programs, using data to implement safe patient handling programs in skilled nursing facilities and hospitals, and collecting meaningful health related and cost data for the WNY region to inform policy makers and better coordinate public and community health.

Dr. Wende has participated in numerous projects and research programs in his career including: the NCI Tobacco Surveillance Measures (ToBIG project), a Monitoring the Future Youth tobacco data project, and ImpacTeen data enhancement project. While Project Director in the Department of Neurology, he supervised data collection for a multi-center randomized drug trial on Avonex® with the Multiple Sclerosis Collaborative Research Group, as well as helping to initiate the New York State Multiple Sclerosis Consortium Registry. He holds an adjunct faculty position in the Department of Social and Preventive Medicine. Karl was corporate epidemiologist at the Eastman Kodak Company from 1999-2005, where he conducted applied occupational epidemiological studies in their working population and updated a longstanding cohort study.


Education:

BS, Chemistry, St. Lawrence University, 1979

MS, Natural Sciences/Epidemiology, University at Buffalo,

Roswell Park Cancer Institute Graduate Division, 1985

PhD, Epidemiology and Community Health, University at Buffalo, 1996


Selected Publications:

Goodkin, D.E., Cookfair, D.L., Wende, K.E., et al., and the Multiple Sclerosis Collaborative Research Group: Inter-and Intrarater Scoring Agreement Using Grades 1.0-3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992; 42:859-863.
 
Jacobs, L.D., Cookfair, D.L., Rudick, R.A., et al., and the Multiple Sclerosis Collaborative Research Group: A Phase III Trial of Intramuscular Recombinant Interferon Beta as Treatment for Exacerbating-remitting Multiple Sclerosis: Design and Conduct of Study and Baseline Characteristics of Patients. Multiple Sclerosis, 1995; 1:118-135..
 
Jacobs, L.D., Cookfair, D.L., Rudick, R.A., et al., and the Multiple Sclerosis Collaborative Research Group: "Intramuscular Interferon β-1a for Disease Progression in Relapsing Multiple Sclerosis." Annals of Neurology 1996; 39 (3): 285-294
 
Simon J, Jacobs L, Campion M, Wende K, Simonian N, Cookfair D, Rudick R, Herndon R, Richert J, Salazar A, Alam J, Fischer J, Goodkin D, Granger C et al, MR studies of intramuscular r-interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group, Annals of Neurology 1998; 43 (1): 79-87.
 
Goodkin D, Priore R, Wende K, Campion M, Bourdette D, Herndon R, Fischer J, Jacobs L, Cookfair D, Rudick R, Richert J, Salazar A, Granger C, Simon J, Alam J, Bartoszak D, Braiman J, Brownscheidle C, Coats M, Cohan S, Dougherty D, Kinkel R, Mass M, Munschauer F, Pullicino P, Scherokman B, Weinstock-Guttman B, Whitham R, Comparing the ability of various composite outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG). Multiple Sclerosis 1998 Dec;4 (6):480-486.
 
Wende K, The future looks bright, Rehab Management 1999 Feb-Mar;12 (2):32-4.
 
Simon J.H., Jacobs L.D., Campion M.K., Rudick R.A., Cookfair D.L., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Simonian N., Lajaunie M., Miller D.E., Wende K.E., Martens Davidson A., Kinkel R.P., Munschauer F.E., Brownscheidle C.M. and The Multiple Sclerosis Collaborative Research Group (MSCRG), A longitudinal study of brain atrophy in relapsing multiple sclerosis, Neurology, 1999, July;53 (1):139-148.
 
Jacobs L, Wende K, Brownscheidle C, Apatoff B, Coyle P, Goodman A, Gottesman M, Granger C, Greenberg S, Herbert J, Krupp L, Lava N, Mihai C, Miller A, Perel A, Smith C, Snyder D, and the New York State Multiple Sclerosis Consortium. A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium, Multiple Sclerosis, 1999,Oct;5 (5):369-76.
 
Rudick RA. Cookfair DL. Simonian NA. Ransohoff RM. Richert JR. Jacobs LD. Herndon RM. Salazar AM. Fischer JS. Granger CV. Goodkin DE. Simon JH. Bartoszak DM. Bourdette DN. Braiman J. Brownscheidle CM. Coats ME. Cohan SL. Dougherty DS. Kinkel RP. Mass MK. Munchsauer FE. O'Reilly K. Priore RL. Pullicino P, Scherokman B, Wende K, Weinstock-Guttman B, Whitham R, Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Journal of Neuroimmunology, 93 (1-2): 8-14,1999 Jan. 1.
 
Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd, A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β-1a. Multiple Sclerosis Collaborative Research Group, Neurology 2000 Jul 25; 55 (2):185-92.
 
Schwid SR, Goodman AD, Apatoff BR, Coyle PK, Jacobs LD, Krupp LB, Miller AE, Wende KE, Brownscheidle CM, New York State Multiple Sclerosis Consortium, Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology 2000 Dec 26;55 (12):1901-3.
 
Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O'Reilly Hovey KM, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF, Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group, Ann Neurol 2000 Dec;48 (6):885-92.
 
Stewart CC, Cookfair DL, Hovey KM, Wende KE, Bell DS, Warner CL. Predictive immunophenotypes: Disease-related profile in chronic fatigue syndrome, Cytometry 2003 May;53B (1):26-33.
Granger CV, Wende KE, Brownscheidle CM, Use of the FIM™ Instrument in a Trial of Intramuscular Interferon β-1a for Disease Progression in Relapsing-Remitting Multiple Sclerosis, Am. J. Phys. Med. Rehabil., June 2003, Vol. 82, No. 6
 
Giovino GA, Chaloupka FJ, Hartman AM, Gerlach Joyce K, Chriqui, J, Orleans CT, Wende K, et al. Cigarette Smoking Prevalence and Policies in the 50 States: An Era of Change - The Robert Wood Johnson Foundation ImpacTeen Tobacco Chart Book. Buffalo, NY: University at Buffalo, State University of New York, 2009.


| About the Center | Mission Statement | Contact the Center | Directory | Research | Funding | Scholarships | Student Opportunities | WSYDC | NYSVAA |
| Center for Development of Human Services | SUNY Buffalo State |
This web site is maintained by the Institute for Community Health Promotion, which is responsible for all content. Copyright . All rights reserved.
Comments may be directed to: chsrctr@buffalostate.edu.